Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Text search

Sort by Random

Display 15 Products per page

Big Pharma Outlook 2015

$3,000.00

Big Pharma is poised for growth due to strong launch portfolios, the availability of high-potential pipeline assets, and companies’ sharpened focus on high-performing markets.
September 28, 2016
Find out more
Afstyla
Read More
Afstyla is a single-chain recombinant factor VIII (rfVIII) product developed by CSL Behring to have a longer duration of action than standard rfVIII. Endogenously produced fVIII consists of a light chain and a heavy chain fused via a metal ion bridge.
May 4, 2018
Find out more
Exelon
Read More
Novartis first launched Exelon as a twice-daily oral formulation in Europe in 1998 and in the US in 2000 for the treatment of mild to moderate Alzheimer’s disease.
September 2, 2016
Find out more
France Generics and Biosimilars

$2,995.00

Traditionally considered an immature generics market, France has seen the introduction of measures aimed at increasing generics use in order to cut healthcare costs.
November 3, 2016
Find out more
Alunbrig
Read More
Alunbrig (brigatinib; Takeda) is a dual anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor.
September 8, 2018
Find out more
Tyvaso for Pulmonary Arterial Hypertension

$89.00

The literature search was undertaken via multiple search engines and strategies with review of cited and associated articles to provide a comprehensive discussion on the topic. Expert opinion: While safe and well tolerated, inhaled treprostinil sodium should be limited, based on available data, to use as add-on therapy for patients with Group I pulmonary hypertension not effectively controlled on oral therapy.
November 29, 2016
Find out more
Bosulif
Read More
Bosulif is a kinase inhibitor that targets the BCR-ABL kinase and also inhibits the Src-family kinases that include Src, Lyn, and Hck. The BCR-ABL kinase is upregulated in the presence of an abnormal BCR-ABL fusion protein…
December 7, 2017
Find out more
Ertugliflozin
Read More
Ertugliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor in Phase III clinical trials for the treatment of type 2 diabetes.
November 7, 2017
Find out more
5EU Surgical Procedure Volumes: Cardiovascular and Peripheral Vascular Procedures

$3,000.00

This report presents procedure volumes forecasts for some of the most common cardiovascular and peripheral vascular surgical procedures performed in the five EU countries of France, Germany, Italy, Spain, and the UK (5EU). The forecast period covered by this report is for the years 2016 through 2021.
December 6, 2017
Find out more
Catch Up On CAR-T

$699.00

Sale!
With the approval of the first CAR-T therapies – Novartis’ Kymriah and Gilead/Kite’s Yescarta – what had been the promise of cutting-edge science is now reality.
November 24, 2017
Find out more
Interventional Cardiology: Atherectomy and Thromboembolectomy

$4,750.00

The global market for atherectomy and thromboembolectomy products is anticipated to see moderate, single-digit growth throughout the forecast period covered by this analysis (2016-22). Growth in unit sales is being driven by the increasing prevalence of cardiovascular disease, which is the leading cause of death globally, responsible for over 17 million deaths annually.
April 5, 2018
Find out more
Alzheimer’s KOL Interview

$399.00

KOL is optimistic on amyloid-targeted therapy and believes IV therapy will be tolerated if approved.
October 21, 2015
Find out more
Elocon
Read More
Elocon is a topical corticosteroid indicated for the relief of the inflammatory and pruritic

manifestations of corticosteroid-responsive dermatoses, including atopic dermatitis, in patients aged

two years and older.
September 28, 2017
Find out more
2015 Breast Cancer Pulse #2

$599.00

This 5-question pulse of 24 oncologists practicing in the United States focuses on the usage of HER2-targeted agents for the treatment of breast cancer.
May 26, 2015
Find out more
Tarceva
Read More
Tarceva (erlotinib; Roche/Chugai/Astellas) is an orally available epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
August 30, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *